Hu W, Li B, Geng N, et al. - Researchers examined links between PDL1 polymorphisms and efficacy of apatinib for patients with previously treated advanced non–small cell lung cancer (NSCLC) in a real-world setting. There were 148 patients with previously treated advanced NSCLC who took part in this study. Clinical efficacy in patients undergoing apatinib treatment was assessed. The objective response rate and disease-control rate of 148 patients was 17.6% and 68.9%, respectively. Concerning PDL1 genetic variation, only rs2297136 was found to have clinical significance. In prognosis analysis, significantly different progression free survival (PFS) and overall survival (OS) for the rs2297136 genotype were revealed. In patients with TC/CC and TT genotypes, the median PFS was estimated to be 3 and 4.5 months, respectively. The median OS of the two genotypes was noted to be 9 and 11.6 months, respectively. No significant association was found between adverse reactions and rs2297136. Thus, experts concluded the likely utility of PDL1 polymorphism rs2297136 as a potential biomarker for prognosis of NSCLC patients receiving apatinib monotherapy.